Financials SUNE BIOP OTC Markets

Equities

SBFM

US8677812054

Pharmaceuticals

Delayed OTC Markets Other stock markets 16:15:16 05/10/2021 BST			5-day change	1st Jan Change
0.1175 ^USD	-1.26%		+0.34%	+657.96%

05-13	Certain Common Stock of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-MAY-2024.	CI
04-19	Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product	MT

Valuation

Fiscal Period: December	2022	2023	2024	2025
Capitalization ¹	14.45	6.972	0.9249	-
Enterprise Value (EV) ¹	14.45	6.972	0.9249	0.9249
P/E ratio	-0.36 x	-1.43 x	1.21 x	0.09 x
Yield	-	-	-	-
Capitalization / Revenue	-	0.29 x	0.02 x	0.01 x
EV / Revenue	-	0.29 x	0.02 x	0.01 x
EV / EBITDA	-	-	-	-
EV / FCF	-	-	-	-
FCF Yield	-	-	-	-
Price to Book	-	-	-	-
Nbr of stocks (in thousands)	226	257	994.5	-
Reference price ²	64.00	27.15	0.9300	0.9300
Announcement Date	04/04/23	28/03/24	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2022	2023	2024	2025
Net sales ¹	-	24.09	44.4	100
EBITDA	-	-	-	-
EBIT ¹	-	-4.785	-0.237	12.06
Operating Margin	-	-19.86%	-0.53%	12.06%
Earnings before Tax (EBT) ¹	-	-4.111	0.8431	12.99
Net income ¹	-26.74	-4.506	0.6831	12.81
Net margin	-	-18.7%	1.54%	12.81%
EPS ²	-176.0	-19.00	0.7700	9.990
Free Cash Flow	-	-	-	-
FCF margin	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-
FCF Conversion (Net income)	-	-	-	-
Dividend per Share	-	-	-	-
Announcement Date	04/04/23	28/03/24	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4
Net sales ¹	5.561	5.958	7.68	7	9	12.6	15.8
EBITDA	-	-	-	-	-	-	-
EBIT ¹	-0.9896	-0.7795	-1.187	-1.293	-0.613	0.3005	1.368
Operating Margin	-17.8%	-13.08%	-15.46%	-18.47%	-6.81%	2.38%	8.66%
Earnings before Tax (EBT) ¹	-0.8144	-0.6105	-1.03	-1.013	-0.343	0.5705	1.629
Net income ¹	-0.9021	-0.6515	-1.25	-1.053	-0.383	0.5305	1.589
Net margin	-16.22%	-10.94%	-16.28%	-15.04%	-4.26%	4.21%	10.05%
EPS ²	-2.000	-4.000	-5.700	-1.040	-0.3700	0.4500	1.340
Dividend per Share	-	-	-	-	-	-	-
Announcement Date	10/08/23	13/11/23	28/03/24	-	-	-	-

¹USD in Million²USD

Estimates

Balance Sheet Analysis

Fiscal Period: December	2022	2023	2024	2025
Net Debt	-	-	-	-
Net Cash position	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-
Free Cash Flow	-	-	-	-
ROE (net income / shareholders' equity)	-	-	-	-
ROA (Net income/ Total Assets)	-	-	-	-
Assets ¹	-	-	-	-
Book Value Per Share	-	-	-	-
Cash Flow per Share	-	-	-	-
Capex	-	-	-	-
Capex / Sales	-	-	-	-
Announcement Date	04/04/23	28/03/24	-	-

¹USD in Million

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for SUNE BIOP

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.93 USD

Average target price

15 USD

Spread / Average Target

+1,512.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals